Skip to main content
SpringerLink
Log in

Antiestrogens: Clinical Applications of Pharmacology

  • Published:
The Journal of the Society for Gynecologic Investigation: JSGI Aims and scope Submit manuscript

Abstract

Selective estrogen receptor modulators (SERMs) appear to reduce the incidence of breast cancer in high-risk women. Five years of tamoxifen administration after the diagnosis of breast cancer results in a 50% reduction in the incidence of contralateral breast cancer. This reduction is maintained for 5 years after therapy is discontinued. The Study of Tamoxifen And Raloxifene (STAR), presently ongoing, will address the questions of breast cancer prevention, risk of endometrial cancer, the incidence of bone fractures, and coronary artery disease in women treated with these SERMs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jordan VC, ed. Tamoxifen for the treatment and prevention of breast cancer. New York, NY: PRR, 1998.

    Google Scholar 

  2. Delmas PD, Bjornason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7.

    Article  CAS  Google Scholar 

  3. Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancer are reduced by raloxifene: Integrated data from multicenter double blind, randomized trials in 12,000 postmenopausal women. Proc Am Soc Clin Oncol (LA) 1998;17(abstract):466.

    Google Scholar 

  4. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer. Eighth Cain Memorial Award Lecture Cancer Res 1990;50:4177–89.

    CAS  PubMed  Google Scholar 

  5. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of randomized clinical trials. Lancet 1998;351:1451–67.

    Article  Google Scholar 

  6. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the NSABP P-1 study. J Natl Cancer Inst 1998;90:1371–88.

    Article  CAS  Google Scholar 

  7. Jordan VC, Morrow M. Tamoxifen, raloxifene and the prevention of breast cancer. Endocrine Rev 1999;20:253–78.

    CAS  Google Scholar 

  8. Jordan VC. Designer estrogens. Sci Am 1998;279:60–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northwestern University Medical School, 303 East Chicago Avenue, Chicago, Illinois, 60611, USA

    V. Craig Jordan PhD, DSc

Authors
  1. V. Craig Jordan PhD, DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jordan, V.C. Antiestrogens: Clinical Applications of Pharmacology. Reprod. Sci. 7 (Suppl 1), S47–S48 (2000). https://doi.org/10.1177/1071557600007001S12

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/1071557600007001S12

Key Words

Search

Navigation